Skip to main content
SteadySharesSteadySharesSteadyStShares
The market
MarketsDiscover
Follow the money
Super InvestorsPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in
Pre-market
SteadySharesMarketsDiscoverSuper InvestorsMy WealthPoliticiansCryptoNews
DiscoverTECH
HealthcareNMSUSD

Bio-Techne Corporation

$0012345678900123456789.0012345678900123456789-0.1%
52w low $43.20$72.69 52w high
Market data · updated 11h ago
Market data
Market cap
$11.16B
52w range
$43.20 - $72.69
Beta
1.29
Sector
Healthcare
Data quality
100/100
Valuation
P/E ratio
102.3x
fair value estimate
$28.64
Margin of safety
-60.4%
Forward P/E
35.0x
PEG ratio
0.96
Dividend yield
0.45%
Quality & efficiency
Moat score
53/100
Return on equity
5.3%
Profit margin
9.0%
Debt / equity
0.14
Growth & analysts
Revenue growth
-1.5%
Analyst target
$70.00
Target upside
-3.3%
Analysts
12
Run the 10-point checklist before you buy How these numbers are made

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Valuation

ValueGrowthProfitHealthIncome29QUALITY
Overall Rating
30
Low quality
Low quality

Derived from filed metrics · High confidence (100% of the inputs available)

Moat Score53
Fair value estimate
$28.64-60.4% downside

Moat, fair value and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
$11.16B
P/E Ratio
102.3
Dividend Yield
0.45%
Revenue Growth
-1.5%
Profit Margin
9.0%
ROE
5.3%
Debt / Equity
0.14
Beta
1.29
Momentum

Statistics

Similar Stocks · Healthcare

Latest News · TECH